vs
Cellectis S.A.（CLLS）与HALOZYME THERAPEUTICS, INC.（HALO）财务数据对比。点击上方公司名可切换其他公司
HALOZYME THERAPEUTICS, INC.的季度营收约是Cellectis S.A.的47.5倍（$451.8M vs $9.5M）。HALOZYME THERAPEUTICS, INC.净利率更高（-31.3% vs -265.9%，领先234.5%）。Cellectis S.A.同比增速更快（375.0% vs 51.6%）。HALOZYME THERAPEUTICS, INC.自由现金流更多（$217.6M vs $27.6M）
Cellectis S.A.是一家法国生物制药公司，专注于开发用于癌症免疫治疗的基因编辑嵌合抗原受体T细胞技术，目前在巴黎、纽约以及北卡罗来纳州罗利均设有办公机构，在肿瘤免疫基因编辑疗法领域拥有多年研发积累。
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
CLLS vs HALO — 直观对比
营收规模更大
HALO
是对方的47.5倍
$9.5M
营收增速更快
CLLS
高出323.4%
51.6%
净利率更高
HALO
高出234.5%
-265.9%
自由现金流更多
HALO
多$190.0M
$27.6M
损益表 — Q2 2024 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $9.5M | $451.8M |
| 净利润 | $-25.3M | $-141.6M |
| 毛利率 | — | 82.6% |
| 营业利润率 | -181.1% | -20.6% |
| 净利率 | -265.9% | -31.3% |
| 营收同比 | 375.0% | 51.6% |
| 净利润同比 | -51.9% | -203.3% |
| 每股收益（稀释后） | $-0.28 | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLLSHALO
| Q4 25 | — | $451.8M | ||
| Q3 25 | — | $354.3M | ||
| Q2 25 | — | $325.7M | ||
| Q1 25 | — | $264.9M | ||
| Q4 24 | — | $298.0M | ||
| Q3 24 | — | $290.1M | ||
| Q2 24 | $9.5M | $231.4M | ||
| Q1 24 | — | $195.9M |
净利润CLLSHALO
| Q4 25 | — | $-141.6M | ||
| Q3 25 | — | $175.2M | ||
| Q2 25 | — | $165.2M | ||
| Q1 25 | — | $118.1M | ||
| Q4 24 | — | $137.0M | ||
| Q3 24 | — | $137.0M | ||
| Q2 24 | $-25.3M | $93.2M | ||
| Q1 24 | — | $76.8M |
毛利率CLLSHALO
| Q4 25 | — | 82.6% | ||
| Q3 25 | — | 84.4% | ||
| Q2 25 | — | 85.8% | ||
| Q1 25 | — | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 82.9% | ||
| Q1 24 | — | 85.5% |
营业利润率CLLSHALO
| Q4 25 | — | -20.6% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.2% | ||
| Q1 25 | — | 53.4% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | -181.1% | 50.7% | ||
| Q1 24 | — | 48.8% |
净利率CLLSHALO
| Q4 25 | — | -31.3% | ||
| Q3 25 | — | 49.5% | ||
| Q2 25 | — | 50.7% | ||
| Q1 25 | — | 44.6% | ||
| Q4 24 | — | 46.0% | ||
| Q3 24 | — | 47.2% | ||
| Q2 24 | -265.9% | 40.3% | ||
| Q1 24 | — | 39.2% |
每股收益（稀释后）CLLSHALO
| Q4 25 | — | $-1.13 | ||
| Q3 25 | — | $1.43 | ||
| Q2 25 | — | $1.33 | ||
| Q1 25 | — | $0.93 | ||
| Q4 24 | — | $1.06 | ||
| Q3 24 | — | $1.05 | ||
| Q2 24 | $-0.28 | $0.72 | ||
| Q1 24 | — | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.0M | $133.8M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | $148.6M | $48.8M |
| 总资产 | $407.1M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 43.89× |
8季度趋势，按日历期对齐
现金及短期投资CLLSHALO
| Q4 25 | — | $133.8M | ||
| Q3 25 | — | $419.7M | ||
| Q2 25 | — | $61.9M | ||
| Q1 25 | — | $176.3M | ||
| Q4 24 | — | $115.8M | ||
| Q3 24 | — | $154.3M | ||
| Q2 24 | $149.0M | $187.9M | ||
| Q1 24 | — | $164.6M |
总债务CLLSHALO
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
股东权益CLLSHALO
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $503.9M | ||
| Q2 25 | — | $332.7M | ||
| Q1 25 | — | $482.3M | ||
| Q4 24 | — | $363.8M | ||
| Q3 24 | — | $452.7M | ||
| Q2 24 | $148.6M | $289.4M | ||
| Q1 24 | — | $177.8M |
总资产CLLSHALO
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | $407.1M | $2.0B | ||
| Q1 24 | — | $1.8B |
负债/权益比CLLSHALO
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.9M | $219.0M |
| 自由现金流经营现金流 - 资本支出 | $27.6M | $217.6M |
| 自由现金流率自由现金流/营收 | 290.5% | 48.2% |
| 资本支出强度资本支出/营收 | 13.2% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $644.6M |
8季度趋势，按日历期对齐
经营现金流CLLSHALO
| Q4 25 | — | $219.0M | ||
| Q3 25 | — | $178.6M | ||
| Q2 25 | — | $99.7M | ||
| Q1 25 | — | $154.2M | ||
| Q4 24 | — | $178.5M | ||
| Q3 24 | — | $115.4M | ||
| Q2 24 | $28.9M | $55.8M | ||
| Q1 24 | — | $129.4M |
自由现金流CLLSHALO
| Q4 25 | — | $217.6M | ||
| Q3 25 | — | $175.6M | ||
| Q2 25 | — | $98.1M | ||
| Q1 25 | — | $153.3M | ||
| Q4 24 | — | $175.4M | ||
| Q3 24 | — | $113.9M | ||
| Q2 24 | $27.6M | $53.2M | ||
| Q1 24 | — | $125.9M |
自由现金流率CLLSHALO
| Q4 25 | — | 48.2% | ||
| Q3 25 | — | 49.6% | ||
| Q2 25 | — | 30.1% | ||
| Q1 25 | — | 57.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 39.3% | ||
| Q2 24 | 290.5% | 23.0% | ||
| Q1 24 | — | 64.3% |
资本支出强度CLLSHALO
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | 13.2% | 1.1% | ||
| Q1 24 | — | 1.8% |
现金转化率CLLSHALO
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLLS
暂无分部数据
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
